mouse lung tumor cell lines resistant to KRAS G12C inhibitor adagrasib
KPAR.E2 and KPAR.M7 cell lines were derived from KPAR1.3 lung tumours resistant to the KRAS G12C inhibitor adagrasib. This experiment aimed to compare the  the transcriptional profile of the resistant cell lines KPAR.E2, KPAR.M7 to the parental cell line KPAR1.3 G12C both at basal level or in response to KRAS G12C inhibition. For this purpose, cells were treated in vitro with DMSO control or the KRAS G12Ci inhibitor adagrasib for 6 or 24 hours.
KPAR.E2 and KPAR.M7 cell lines were derived from KPAR1.3 lung tumours resistant to the KRAS G12C inhibitor adagrasib. This experiment aimed to compare the  the transcriptional profile of the resistant cell lines KPAR.E2, KPAR.M7 to the parental cell line KPAR1.3 G12C both at basal level or in response to KRAS G12C inhibition. For this purpose, cells were treated in vitro with DMSO control or the KRAS G12Ci inhibitor adagrasib for 6 or 24 hours.
FRANCIS CRICK INSTITUTE